Disease · MONDO_0007256

hepatocellular carcinoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. hepatocellular carcinoma. Diseases, record MONDO_0007256. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0007256

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: hepatocellular carcinoma; Open Targets
Open Targets ID: MONDO_0007256; Open Targets
Other names: HCC, cancer, hepatocellular, carcinoma of liver, carcinoma of liver cells, carcinoma of the liver cells, carcinoma, hepatocellular, malignant, hepatoblastoma, somatic, hepatocellular adenocarcinoma, hepatocellular cancer, hepatocellular cancer, somatic, hepatocellular carcinoma, childhood type, somatic, hepatocellular carcinoma, somatic, hepatoma, liver and intrahepatic bile duct carcinoma, liver carcinoma, liver cell cancer (hepatocellular carcinoma), liver cell carcinoma, liver heptocellular carcinoma, primary carcinoma of liver cells, primary carcinoma of the liver cells; Open Targets
Disease Ontology: DOID:684; Disease Ontology
Disease Ontology: DOID:686; Disease Ontology
MeSH: D006528; MeSH
NCI Thesaurus: C3099; NCI Thesaurus
Orphanet: ORPHA:88673; Orphanet
Highest stage of its drugs: Approval, for 8 of its 478 drugs, from ClinicalTrials.gov, EMA Human Drugs, FDA, PMDA and TTD; Open Targets

Drugs478

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
SORAFENIB	CHEMBL1336	Small molecule	Approval	EMA Human Drugs	211	208	208	Drugs and targets
OXALIPLATIN	CHEMBL414804	Small molecule	Approval	ClinicalTrials.gov	101	101	91	Drugs and targets
FLUOROURACIL	CHEMBL185	Small molecule	Approval	ClinicalTrials.gov	88	88	82	Drugs and targets
DURVALUMAB	CHEMBL3301587	Antibody	Approval	ClinicalTrials.gov	73	72	72	Drugs and targets
TREMELIMUMAB	CHEMBL2108658	Antibody	Approval	ClinicalTrials.gov, EMA Human Drugs, FDA, PMDA and TTD	53	49	49	Drugs and targets
LEUCOVORIN	CHEMBL1679	Small molecule	Approval	ClinicalTrials.gov	39	39	39	Drugs and targets
CABOZANTINIB	CHEMBL2105717	Small molecule	Approval	EMA Human Drugs	29	28	28	Drugs and targets
ALCOHOL	CHEMBL545	Small molecule	Approval	PMDA	4	3	1	Drugs and targets
LENVATINIB	CHEMBL1289601	Small molecule	Phase 3	ClinicalTrials.gov and TTD	213	212	212	Drugs and targets
BEVACIZUMAB	CHEMBL1201583	Antibody	Phase 3	ClinicalTrials.gov	200	199	193	Drugs and targets

1 to 10 of 478

See all 478 drugs

Targets397

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
KDR	Vascular endothelial growth factor receptor	30	Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor inhibitor	Approval	https://conductscience.org/library/genes/3791	Drugs and targets
FLT4	Vascular endothelial growth factor receptor	23	Vascular endothelial growth factor receptor 3 inhibitor; Vascular endothelial growth factor receptor inhibitor	Approval	https://conductscience.org/library/genes/2324	Drugs and targets
PDCD1	Programmed cell death protein 1	22	Programmed cell death protein 1 antagonist; Programmed cell death protein 1 inhibitor	Phase 3	https://conductscience.org/library/genes/5133	Drugs and targets
FLT1	Vascular endothelial growth factor receptor	21	Vascular endothelial growth factor receptor 1 inhibitor; Vascular endothelial growth factor receptor inhibitor	Approval	https://conductscience.org/library/genes/2321	Drugs and targets
PDGFRB	Platelet-derived growth factor receptor	17	Platelet-derived growth factor receptor beta inhibitor; Platelet-derived growth factor receptor inhibitor	Approval	https://conductscience.org/library/genes/5159	Drugs and targets
KIT	Mast/stem cell growth factor receptor Kit	15	Stem cell growth factor receptor inhibitor	Approval	https://conductscience.org/library/genes/3815	Drugs and targets
EGFR	Epidermal growth factor receptor	13	Epidermal growth factor receptor erbB1 inhibitor; Epidermal growth factor receptor inhibitor	Phase 3	https://conductscience.org/library/genes/1956	Drugs and targets
PDGFRA	Platelet-derived growth factor receptor	11	Platelet-derived growth factor receptor alpha inhibitor; Platelet-derived growth factor receptor inhibitor	Phase 3	https://conductscience.org/library/genes/5156	Drugs and targets
FGFR1	Fibroblast growth factor receptor	10	Fibroblast growth factor receptor 1 inhibitor; Fibroblast growth factor receptor inhibitor	Phase 3	https://conductscience.org/library/genes/2260	Drugs and targets
MET	Hepatocyte growth factor receptor	10	Hepatocyte growth factor receptor antagonist; Hepatocyte growth factor receptor inhibitor	Approval	https://conductscience.org/library/genes/4233	Drugs and targets

1 to 10 of 397

See all 397 targets

Trials1,505

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 59 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02292706	A Registry for Participants With Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment With a Sofosbuvir-Based Regimen Without Interferon for Chronic Hepatitis C Infection		1,609	2023-10-04	Hepatitis C Virus Infection	LEDIPASVIR, RIBAVIRIN, SOFOSBUVIR, VELPATASVIR, VOXILAPREVIR	Its record names the disease	ClinicalTrials.gov
NCT01968109	An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors	Phase 1/2	1,482	2026-01-06	Neoplasms by Site	NIVOLUMAB, RELATLIMAB	Its record names the disease	ClinicalTrials.gov
NCT03298451	Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma	Phase 3	1,324	2023-06-18	Hepatocellular Carcinoma	DURVALUMAB, TREMELIMUMAB	Its record names the disease	ClinicalTrials.gov
NCT00699374	Study Of Sunitinib Malate Versus Sorafenib In Patients With Inoperable Liver Cancer	Phase 3	1,075	2013-01-14	Carcinoma, Hepatocellular	SORAFENIB, SUNITINIB	Its record names the disease	ClinicalTrials.gov
NCT01761266	A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma	Phase 3	954	2018-09-25	Hepatocellular Carcinoma (HCC)	LENVATINIB, SORAFENIB	Its record names the disease	ClinicalTrials.gov
NCT01465464	Orantinib In Combination With Transcatheter Arterial Chemoembolization In Patients With Unresectable Hepatocellular Carcinoma	Phase 3	888	2019-08-07	Hepatocellular Carcinoma	ORANTINIB	Its record names the disease	ClinicalTrials.gov
NCT03755791	Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Received Previous Systemic Anticancer Therapy	Phase 3	837	2025-12-11	Hepatocellular Carcinoma	ATEZOLIZUMAB, CABOZANTINIB	Its record names the disease	ClinicalTrials.gov
NCT03713593	Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002)	Phase 3	794	2023-07-24	Carcinoma, Hepatocellular	LENVATINIB, PEMBROLIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT02576509	An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma	Phase 3	743	2020-06-26	Hepatocellular Carcinoma	NIVOLUMAB, SORAFENIB	Its record names the disease	ClinicalTrials.gov
NCT00901901	Nexavar-Tarceva Combination Therapy for First Line Treatment of Patients Diagnosed With Hepatocellular Carcinoma	Phase 3	732	2013-09-30	Carcinoma, Hepatocellular	ERLOTINIB, SORAFENIB	Its record names the disease	ClinicalTrials.gov

1 to 10 of 1,505

See all 1,505 trials

Comparisons in its trials180

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Sunitinib vs Sorafenib: serious adverse events	240 of 526	204 of 542	1,068	NCT00699374	Trial comparisons
Lenvatinib vs Sorafenib: deaths from any cause	415 of 478	402 of 476	954	NCT01761266	Trial comparisons
Lenvatinib vs Sorafenib: serious adverse events	209 of 476	149 of 475	951	NCT01761266	Trial comparisons
Orantinib vs Placebo: deaths from any cause	33 of 444	24 of 444	888	NCT01465464	Trial comparisons
Orantinib vs Placebo: serious adverse events	200 of 444	134 of 444	888	NCT01465464	Trial comparisons
Lenvatinib + Pembrolizumab vs Lenvatinib + Placebo: deaths from any cause	314 of 395	352 of 399	794	NCT03713593	Trial comparisons
Lenvatinib + Pembrolizumab vs Lenvatinib + Placebo: Number of Participants Who Discontinued Study Drug Due to an Adverse Event	51 of 395	41 of 395	790	NCT03713593	Trial comparisons
Lenvatinib + Pembrolizumab vs Lenvatinib + Placebo: Number of Participants Who Experienced an Hepatic Event of Clinical Interest (HECI)	71 of 395	77 of 395	790	NCT03713593	Trial comparisons
Lenvatinib + Pembrolizumab vs Lenvatinib + Placebo: Number of Participants Who Experienced an Immune-related Adverse Event (irAE) of Clinical Interest	210 of 395	184 of 395	790	NCT03713593	Trial comparisons
Lenvatinib + Pembrolizumab vs Lenvatinib + Placebo: Number of Participants Who Experienced an Serious Adverse Event (SAE)	185 of 395	159 of 395	790	NCT03713593	Trial comparisons

1 to 10 of 180

See all 180 comparisons in its trials

Papers from its trials718

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
41607859	RESULT	1	PubMed
41125112	RESULT	2	PubMed
39986353	RESULT	1	PubMed
39915447	RESULT	1	PubMed
39798578	RESULT	1	PubMed
39792482	RESULT	1	PubMed
39699905	RESULT	2	PubMed
39435268	RESULT	1	PubMed
38898592	RESULT	1	PubMed
38745965	RESULT	1	PubMed

1 to 10 of 718

See all 718 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0007256

GET https://conductscience.org/api/diseases/v1/MONDO_0007256/drugs?page=2

API reference For AI assistants